is it time?, page-2

hi inky.

Possibly because the big seller has finally sold up.

Insomniac said "Qld Invest. Corp sold their entire CCE holding and entire biotech portfolio".

Also the news that the first patient to have been treated with Cellspray xp, would have helped.

Hopefully next we will have US approval for Recell.

If you look at Aussie biotecs with a mkt cap of $200m to $400m, it's hard to work out why cce are only at $80m. The market will adjust eventually, like they did with pxs. Perhaps the price has stayed low, because it has stayed low for so long - investors aren't realising that the share price should be between $1 & $2, with lots of upside potential (again, like pxs).

Any thoughts out there?